Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
Reported purchases exceed sales by $29.4MOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
Company profile
GlycoMimetics Inc is a biotechnology company in the healthcare sector.
Company profile compiled from available company records. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 23, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Fairmount Funds Management Llc | Director | Jul 16 '26 | Buy | $14.50 | 853,450 | $12,375,025 | 3,601,316 | Jul 20 05:30 PM |
| Lynch Ryan | See Remarks | Jun 22 '26 | Sale | $17.99 | 465 | $8,365 | 13,871 | Jun 23 04:04 PM |
| Pinkas Jan | Chief Scientific Officer | Jun 22 '26 | Sale | $17.99 | 1,288 | $23,171 | 22,239 | Jun 23 04:04 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.